Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe page's revision label was updated from v3.6.6 to v3.7.0. This indicates a behind-the-scenes maintenance release rather than a visible change to the content or layout.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page's revision label changed from v3.6.5 to v3.6.6, indicating a newer version of the page. This update reflects an updated page revision without altering the study data.SummaryDifference0.0%

- Check25 days agoChange DetectedAn NIH funding line, '2018 ( U.S. NIH Grant/Contract )', was added to the funding information section, signaling NIH support for the LEAP-004 trial. This provides background on the source of funding for the study.SummaryDifference0.0%

- Check39 days agoChange DetectedFooter now displays Revision: v3.6.5, replacing the previous Revision: v3.6.4. This update reflects a page revision and does not affect the study details or user-facing content.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4, indicating a new build of the page.SummaryDifference0.0%

- Check82 days agoChange DetectedThe revision label in the study documents section was updated from v3.6.0 to v3.6.3, indicating a newer version of the protocol/document referenced on the page.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.